Literature DB >> 6436530

Human plasma lipoproteins and total parenteral nutrition with intravenous fat emulsion.

R H Judd, H Freund, R J Deckelbaum.   

Abstract

Lipoprotein concentration and composition before and after Intralipid infusion were investigated in seven adult surgical patients receiving continuous total parenteral nutrition. Plasma samples were obtained prior to parenteral alimentation, after 7 days of glucose/amino acid solution without Intralipid, and again following 5 days of daily Intralipid. Cholesterol, triglyceride, protein, and phospholipid concentrations were determined on very low-, low-, and high-density lipoprotein from each specimen. After Intralipid very low-density lipoprotein concentration fell to 29% (p less than 0.015) of pre-Intralipid levels. There was no substantial increase in low-density lipoprotein phospholipid post-Intralipid to suggest the presence of lipoprotein-X. Plasma total triglyceride levels declined by 33% after Intralipid (p less than 0.01) and plasma total cholesterol levels rose by 40% (p less than 0.02). In our patients, in whom metabolic mechanisms were not saturated, it would appear that Intralipid was metabolized by activated lipoprotein lipase pathways, without the appearance of hyperlipidemia or abnormal lipoproteins.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6436530     DOI: 10.1177/0148607184008005552

Source DB:  PubMed          Journal:  JPEN J Parenter Enteral Nutr        ISSN: 0148-6071            Impact factor:   4.016


  2 in total

1.  Hypocaloric peripheral parenteral nutrition with lipid emulsion in postoperative gastrointestinal cancer patients.

Authors:  Chien-Yu Lu; Hung-Yi Chuang; Fang-Jung Yu; Li-Chu Sun; Ying-Ling Shih; Fang-Ming Chen; Jan-Sing Hsieh; Jaw-Yuan Wang
Journal:  World J Gastrointest Oncol       Date:  2010-01-15

Review 2.  Atrial fibrillation.

Authors:  Bianca J J M Brundel; Xun Ai; Mellanie True Hills; Myrthe F Kuipers; Gregory Y H Lip; Natasja M S de Groot
Journal:  Nat Rev Dis Primers       Date:  2022-04-07       Impact factor: 52.329

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.